Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024
BBL will gain Viatris’ global biosimilars business whose revenues are estimated to be USD 1 billion next year, along with its portfolio of in-licensed biosimilar assets
Revenue of $1.67 billion represents 8% reported growth; and up 9% on a core(basis.
Darolutamide is developed jointly by Bayer and Orion Corporation
AptarGroup acquired Voluntis and 80% of Weihai Hengyu Medical Products in 2021.
The companies will continue with their exclusive agreements, including commercialization of their current portfolio
The tablet donations provided for the treatment of more than 600 million schoolchildren in affected countries in sub-Saharan Africa since 2007
It accelerates the company’s vision for transforming healthcare and advancing patient care worldwide – from the hospital to the home
The agreement will sharpen Cigna's focus on the growth path for its rapidly expanding global health portfolio
The transaction is anticipated to close in the first quarter of 2022
Subscribe To Our Newsletter & Stay Updated
